Cyclosporin A suppresses insulin autoantibodies and heterologous insulin antibodies in type I diabetic children.
We report that cyclosporin A (CsA) suppresses the insulin autoantibodies that are present before insulin therapy in the sera of one-third of studied type I (insulin-dependent) diabetic children. CsA also reversibly blocks the production of antibodies after exogenous insulin injection, whereas high titers of heterologous insulin antibody are observed in all type I patients not receiving CsA.
Castaño
L
L
Institut National de la Santé et de la Recherche Médicale (U 188), Hôpital St Vincent de Paul, Paris, France.
Boîtard
C
C
Bougnères
P F
PF
D001323:Autoantibodies / Q000096:biosynthesis*; D002648:Child; D003524:Cyclosporins / Q000494:pharmacology*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000276:immunology*; D006801:Humans; D007328:Insulin / Q000097:blood / Q000627:therapeutic use*; D007330:Insulin Antibodies / Q000096:biosynthesis*
D001323:Autoantibodies; D003524:Cyclosporins; D007328:Insulin; D007330:Insulin Antibodies; C024211:islet cell antibody